Search

Displaying results 6491 - 6500 of 10000 in total
  1. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis.

  2. Drug

    OSI-7904L

    go.drugbank.com/drugs/DB05457
    Investigational

    OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA).

  3. Drug

    Albumin iodinated I-131 serum

    go.drugbank.com/drugs/DB09430
    Approved

    Iodinated I-131 serum albumin is a radiopharmaceutical agent used for several diagnostic purposes, including the determination of body fluid volumes and the imaging of certain tissues.

  4. Drug

    Noxytiolin

    go.drugbank.com/drugs/DB13838
    Approved

    Local antibacterial that probably acts by releasing formaldehyde in aqueous solutions.

  5. Drug

    Praliciguat

    go.drugbank.com/drugs/DB16300
    Investigational

    Praliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).

  6. Drug

    KITE-585

    go.drugbank.com/drugs/DB17409
    Investigational

    KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.

  7. Drug

    AZD8630

    go.drugbank.com/drugs/DB19397
    Investigational

    AZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics

  8. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  9. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.

  10. Drug

    Fucoxanthin

    go.drugbank.com/drugs/DB15462
    Investigational

    In vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. … Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).